Serum markers such as IL-6 and MCP-1 are significantly altered in the early stages of kidney injury, and the detection of relevant molecular markers in peripheral blood provides a novel auxiliary reference for the clinical management of diabetic nephropathy. This evidence concerns the gene CCL2 and diabetic kidney disease.